Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 16/20 | 0.52 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3479447 | 0.95 | BACE1 (0.48) | BACE1HCRTR1HCRTR2TACR1 | |
| SCHEMBL3479509 | 0.87 | BACE1 (0.64) | BACE1 | |
| SCHEMBL3479463 | 0.87 | BACE1 (0.64) | BACE1 | |
| SCHEMBL3479630 | 0.87 | BACE1 (0.64) | BACE1 | |
| SCHEMBL3479620 | 0.87 | CACNA1F (0.41) | BACE1TACR1 | |
| SCHEMBL3479542 | 0.86 | BACE1 (0.45) | BACE1 | |
| SCHEMBL13031031 | 0.86 | BACE1 (0.45) | BACE1 | |
| Trifluoroacetic Acid SCHEMBL3479366 | 0.83 | BACE1 (0.41) | BACE1 | |
| Trifluoroacetic Acid SCHEMBL3479659 | 0.83 | BACE1 (0.41) | BACE1 | |
| Trifluoroacetic Acid SCHEMBL3479500 | 0.82 | BACE1 (0.58) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298342-A1 | Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease | MERCK & CO., INC. (US) | 2010-11-25 | — | — | US | claimed |
| US-20100298342-A1 | Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease | MERCK & CO., INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100298342-A1 | Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease | MERCK & CO., INC. (US) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298342-A1 | Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease | BACE1, APP, PSEN1 | BACE1 1/4885HCRTR1 1747/4885HCRTR2 1248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.